SENSORION SA (ALSEN.PA) Stock Price & Overview

EPA:ALSEN • FR0012596468

Current stock price

0.66 EUR
-0.04 (-5.71%)
Last:

The current stock price of ALSEN.PA is 0.66 EUR. Today ALSEN.PA is down by -5.71%. In the past month the price increased by 95.27%. In the past year, price increased by 17.44%.

ALSEN.PA Key Statistics

52-Week Range0.1544 - 0.808
Current ALSEN.PA stock price positioned within its 52-week range.
1-Month Range0.292 - 0.808
Current ALSEN.PA stock price positioned within its 1-month range.
Market Cap
339.867M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.09
Dividend Yield
N/A

ALSEN.PA Stock Performance

Today
-5.71%
1 Week
+63.77%
1 Month
+95.27%
3 Months
+95.85%
Longer-term
6 Months +116.39%
1 Year +17.44%
2 Years -14.17%
3 Years +88.57%
5 Years -71.05%
10 Years N/A

ALSEN.PA Stock Chart

SENSORION SA / ALSEN Daily stock chart

ALSEN.PA Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to ALSEN.PA. When comparing the yearly performance of all stocks, ALSEN.PA is one of the better performing stocks in the market, outperforming 96.27% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ALSEN.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ALSEN.PA. ALSEN.PA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALSEN.PA Earnings

Next Earnings DateN/A
Last Earnings DateMar 12, 2026
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise -100.00%

ALSEN.PA Forecast & Estimates

14 analysts have analysed ALSEN.PA and the average price target is 1.94 EUR. This implies a price increase of 193.64% is expected in the next year compared to the current price of 0.66.


Analysts
Analysts87.14
Price Target1.94 (193.94%)
EPS Next Y0%
Revenue Next Year-9.07%

ALSEN.PA Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

ALSEN.PA Financial Highlights

Over the last trailing twelve months ALSEN.PA reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 9.26% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-28.09M
Industry RankSector Rank
PM (TTM) N/A
ROA -38.3%
ROE -49.29%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%-1.33%
Sales Q2Q%N/A
EPS 1Y (TTM)9.26%
Revenue 1Y (TTM)N/A

ALSEN.PA Ownership

Ownership
Inst Owners31.19%
Shares514.95M
Float426.27M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

ALSEN.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ARGX ARGENX SE25.1137.984B
1AE ARGENX SE25.1837.885B
22UA BIONTECH SE-ADR N/A18.924B
2X1 ABIVAX SA N/A8.018B
ABVX ABIVAX SA N/A8.002B
GXE GALAPAGOS NV N/A1.824B
GLPG GALAPAGOS NV N/A1.82B
NANO NANOBIOTIX N/A1.396B
6IV INVENTIVA SA N/A1.087B
IVA INVENTIVA SA N/A1.067B
PHIL PHILOGEN SPA17.77660.824M
XUP GENFIT917.65468.027M
GNFT GENFIT832.84424.525M

About ALSEN.PA

Company Profile

ALSEN logo image Sensorion SA is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo, and tinnitus. The company is headquartered in Montpellier, Occitanie and currently employs 68 full-time employees. The company went IPO on 2015-04-21. The firm is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The firm develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.

Company Info

IPO: 2015-04-21

SENSORION SA

375, rue du Professeur Joseph Blayac

Montpellier OCCITANIE FR

Employees: 63

ALSEN Company Website

ALSEN Investor Relations

Phone: 33467207730

SENSORION SA / ALSEN.PA FAQ

What does SENSORION SA do?

Sensorion SA is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo, and tinnitus. The company is headquartered in Montpellier, Occitanie and currently employs 68 full-time employees. The company went IPO on 2015-04-21. The firm is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The firm develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.


Can you provide the latest stock price for SENSORION SA?

The current stock price of ALSEN.PA is 0.66 EUR. The price decreased by -5.71% in the last trading session.


What is the dividend status of SENSORION SA?

ALSEN.PA does not pay a dividend.


What is the ChartMill technical and fundamental rating of ALSEN stock?

ALSEN.PA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the market capitalization of ALSEN stock?

SENSORION SA (ALSEN.PA) has a market capitalization of 339.87M EUR. This makes ALSEN.PA a Small Cap stock.